SGLT2 Inhibitor And GLP-1 Receptor Agonist in Type 2 Diabetes Mellitus Patients. Research on Their Cardiovascular Benefits

Leicheng He

doi:10.54097/m9vm2798

Authors

Leicheng He

DOI:

https://doi.org/10.54097/m9vm2798

Keywords:

Type 2 diabetes mellitus; SGLT2 inhibitors; glucagon like peptide 1 (GLP-1) receptor agonist; cardiovascular.

Abstract

The health of people is now seriously threatened by diabetes. Type 2 diabetes mellitus’ patients are prone to microvascular diseases, which is a cardiovascular disease risk factor. In T2DM patients, it has been demonstrated that sodium-glucose co-transporters (SGLT2) inhibitors have positive cardiovascular effects, glucagon like peptide 1 (GLP-1) receptor agonist also exhibited similar effect on cardiovascular. In recent, noteworthy trials, GLP-1RAs and SGLT-2Is have demonstrated effective cardiac protection and safety in high-risk T2DM patients, which is a new force in T2DM drug therapy.

Downloads

Download data is not yet available.

References

Vallon, V. and S. Verma, Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annual review of physiology, 2021. 83: p. 503-528.

Seidu, S., et al., SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Primary Care Diabetes, 2018. 12(3): p. 265-283.

Rabizadeh, S., M. Nakhjavani, and A. Esteghamati, Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review. International journal of endocrinology and metabolism, 2019. 17(2).

Vallon, V. and S.C. Thomson, Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia, 2017. 60(2): p. 215-225.

Filippatos, T.D., et al., SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgraduate Medicine, 2019. 131(2): p. 82-88.

Zhao, Y., et al., Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018. 20(2): p. 458-462.

Lu Yunhong and Chen Liming, SGLT2 inhibitors and hyperuricemia. Chinese Journal of Practical Internal Medicine, 2020. 40(8): p. 625-629.

Qi and Liu Jing, Cardioprotective effects of SGLT2 inhibitors. Chinese Journal of Practical Internal Medicine, 2020. 40(8): p. 630-633.

Patel, V.B., et al., Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart failure reviews, 2017. 22(6): p. 889-902.

Wei Han, et al., Research progress on SGLT⁃ 2 inhibitors in improving cardiovascular disease prognosis in patients with diabetes. Journal of Nanjing Medical University (Natural Science Edition), 2020(5): p. 773-778.

Okamoto, A., et al., Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs in R&D, 2016. 16: p. 255-261.

Baartscheer, A., et al., Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia, 2017. 60: p. 568-573.

Abbasi, F., et al., Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism, 2004. 53(2): p. 159-164.

Verma, S., et al., Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes care, 2016. 39(12): p. e212-e213.

Polidori, D., et al., Intra‐and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin. Diabetes, Obesity and Metabolism, 2018. 20(5): p. 1321-1326.

Sun Yihao, Li Binghan, and Guo Yan, Research progress on SGLT-2 inhibitors in the treatment of diabetes. Shandong Medicine, 2017. 57(46): p. 110-113.

Wang Lin, Research progress on SGLT2 inhibitors in the treatment of heart failure. Chinese Prescription Drugs, 2022. 20(9): p. 192-194.

Zhu Yi and Feng Yufei, Pharmacology and clinical evaluation of the GLP-1 receptor agonist semaglutide. Journal of Clinical Drug Therapy, 2018. 16(3): p. 17-21.

Wang, W., et al., Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Therapy, 2017. 8(4): p. 727-738.

Chen Hong and Lai Wenwen, Research progress on the protective effect of glucagon-like peptide 1 receptor agonists on the cardiovascular system in obesity and diabetes. Journal of Rational Clinical Drug Use, 2021. 14(9): p. 174-176.

Liang Haili and Lu Ying, Research progress on the cardiovascular protective effects and mechanisms of GLP-1 receptor agonists in patients with type 2 diabetes. Modern Chinese Physicians, 2023. 61(6): p. 121-123.

Zheng Xin, Zhu Yugang, and Wang Defeng, Systematic review of the effects of GLP-1 receptor agonists on pancreatic islet cell function in overweight and obese patients with type 2 diabetes. Journal of Clinical Metaphysics, 2019. 34(12): p. 1102-1107.

Li Jingjing and Sun Lijuan, Effects of glucagon-like peptide-1 receptor agonist on cardiac function in patients with type 2 diabetes and coronary heart disease. Chinese Experimental Diagnostics, 2020. 24(3): p. 450-451.

Yu Yinan, Liang Li, and Xin Shuangqing, Effects of GLP-1 receptor agonists on myocardial and vasodilation function in patients with type 2 diabetes. Practical Pharmacy & Clinical Remedies, 2018. 21(11).

Gaspari, T., et al., A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diabetes and Vascular Disease Research, 2011. 8(2): p. 117-124.

Wang Honglei, et al., Study on the mechanism of liraglutide reducing ischemia-reperfusion injury of myocardial microcirculatory endothelial cells. Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Diseases, 2017. 19(8): p. 858-866.

Liu Jingjing, Wei Li, and Wang Jianbo, Research progress on the effects of GLP-1 receptor agonists on vascular lesions in patients with type 2 diabetes. CHINA MEDICAL HERALD, 2017. 14(18).

Jin Lingyi, Z.J., Qiu Jiaping, The significance of glucagon-like peptide-1 analogues in the treatment of type 2 diabetes [J]. Journal of Clinical Rational Drug Use, 2020.